Pfizer sells Chinese IP to seal Wyeth deal
US pharmaceutical company Pfizer has sold the Chinese IP rights for a swine flu vaccine to a domestic company to comply with an anti-monopoly review by the Chinese Ministry of Commerce
The world's largest research-based drug maker has sold the
Chinese patent rights to Harbin Pharmaceutical Group and will
provide the company with technical assistance and training on
how to use the vaccine for up to three years.
"This is the...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.